MET and invasive breast carcinoma: HGF is the only known ligand for cMET, and the HGF/cMET signaling pathway has long been studied in normal development, ductal morphogenesis (Garner et al. 2011), invasive breast cancer (Tuck et al. 1996; Yamashita et al. 1994; Elliott et al. 2002; Wang et al. 1994; Jin et al. 1997; Beviglia et al. 1997), and invasive biology of several other cancers due to its angiogenic, mitogenic, and morphogenic effects (Stella et al. 2005; Sam et al. 2007).